From ASCO: Updates in HER2-positive breast cancers

DEBU TRIPATHY
PUBLISHED: 5:17 PM, WED JUNE 5, 2013
Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
Debu Tripathy blog image

Debu Tripathy, MD, editor-in-chief of CURE, discusses preliminary studies on combining Herceptin (trastuzumab) with existing drugs to treat HER2-positive breast cancer. These highlighted studies were presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.



Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
Special Feature
Share Your Art
Related Articles
Cancer: Advice for Dealing With the Financial Burden
Hear financial expert and registered nurse Mary Ann Cagle discuss the financial burden of cancer, often a result of expensive treatments, appointments, and diagnostic tests. Learn where to look for possible financial support.
$auto_registration$